Taxanes prodrug-based nanomedicines for cancer therapy

Sun, Lan; Zhao, Pan; Chen, Menghan; Leng, Jiayi; Luan, Yixin; Du, Bao-Xiang; Yang, Jia; Yang, Yong; Rong, Rong

doi:10.1016/j.jconrel.2022.06.004

Cited by 16 publications

(9 citation statements)

References 220 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 In the past twenty years, prodrug nanomedicines have been extensively explored for cancer therapy. [25][26][27] These delivery platforms effectively protect the encapsulated agents from degradative processes, such as metabolism and hydrolysis. 28 More importantly, nanomedicines could considerably improve the tumor-targeting ability of the drugs via the enhanced permeability and retention (EPR) effect.…”

Section: Chao Wangmentioning

confidence: 99%

Camptothecin-based prodrug nanomedicines for cancer therapy

Zhang,

Yu,

Guo

et al. 2023

Nanoscale

View full text Add to dashboard Cite

show abstract

Section: Chao Wangmentioning

confidence: 99%

Camptothecin-based prodrug nanomedicines for cancer therapy

Zhang,

Yu,

Guo

et al. 2023

Nanoscale

View full text Add to dashboard Cite

show abstract

“…The self-assembled polymeric prodrug micelles are very stable in a physiological environment and can reduce unwanted drug leakage of drugs before reaching tumor tissue, thereby effectively inhibiting side effects of chemotherapeutic drugs on normal cells ( Sun et al, 2018 ; Shukla et al, 2022 ; Sun et al, 2022 ). The polymeric prodrug micelles not only have the advantages of improved chemical stability, high DLC and low side effects, but they can also be used as drug carriers, thereby constituting a multidrug codelivery system that can be used for combination therapy and for improving therapeutic efficacy ( Li S. et al, 2020 ; Ma et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

A co-delivery system based on chlorin e6-loaded ROS-sensitive polymeric prodrug with self-amplified drug release to enhance the efficacy of combination therapy for breast tumor cells

Wang

Yang

Qiu

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Background: Recently, various combination therapies for tumors have garnered popularity because of their synergistic effects in improving therapeutic efficacy and reducing side effects. However, incomplete intracellular drug release and a single method of combining drugs are inadequate to achieve the desired therapeutic effect.Methods: A reactive oxygen species (ROS)-sensitive co-delivery micelle (Ce6@PTP/DP). It was a photosensitizer and a ROS-sensitive paclitaxel (PTX) prodrug for synergistic chemo-photodynamic therapy. Micelles size and surface potential were measured. In vitro drug release, cytotoxicity and apoptosis were investigated.Results: Ce6@PTP/DP prodrug micelles exhibited good colloidal stability and biocompatibility, high PTX and Ce6 loading contents of 21.7% and 7.38%, respectively. Upon light irradiation, Ce6@PTP/DP micelles endocytosed by tumor cells can generate sufficient ROS, not only leading to photodynamic therapy and the inhibition of tumor cell proliferation, but also triggering locoregional PTX release by cleaving the thioketal (TK) bridged bond between PTX and methoxyl poly (ethylene glycol). Furthermore, compared with single drug-loaded micelles, the light-triggered Ce6@PTP/DP micelles exhibited self-amplified drug release and significantly greater inhibition of HeLa cell growth.Conclusion: The results support that PTX and Ce6 in Ce6@PTP/DP micelles exhibited synergistic effects on cell-growth inhibition. Thus, Ce6@PTP/DP micelles represent an alternative for realizing synergistic chemo-photodynamic therapy.

show abstract

“…Cancer and bacillosis remain major threats to human health, and the exploitation of efficient chemotherapy for restraining or killing them has become a global focus. [1][2][3] Although many drugs with promising antitumor or antiviral activities, such as curcumin, vincristine, paclitaxel and quinolones, have been reported, [4][5][6] the low solubility is still a major obstacle limiting their clinical application. 7 The common means of intravenous administration will cause either aggregation, which may create safety problems, or inadequate drug doses at the target site with low bioavailability due to low solubility.…”

Section: Introductionmentioning

confidence: 99%